Kim CG, Sohn J, Chon H, Kim JH, Heo SJ, Cho H, Kim IJ, Kim SI, Park S, Park HS, Kim GM
PURPOSE: Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%–20%) for febrile neutropenia (FN) in breast cancer. However, the reported incidence of FN while using...